{"id":"gentamicin-sulfate-injectable","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nephrotoxicity (acute kidney injury)"},{"rate":"3-14","effect":"Ototoxicity (hearing loss, tinnitus, vertigo)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Neuromuscular blockade"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gentamicin irreversibly binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA codons and preventing proper protein synthesis. This bactericidal action is particularly effective against aerobic gram-negative bacteria and some gram-positive organisms. The drug is concentration-dependent, meaning higher peak concentrations produce greater bacterial killing.","oneSentence":"Gentamicin sulfate is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:59.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious gram-negative bacterial infections (sepsis, urinary tract infections, respiratory tract infections)"},{"name":"Gram-positive infections in combination therapy"},{"name":"Empiric therapy for suspected aerobic gram-negative infections"}]},"trialDetails":[{"nctId":"NCT05766670","phase":"PHASE3","title":"Intramedullary Calcium Sulfate Antibiotic Depot","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-04-08","conditions":"Open tíbia Fracture, Osteomyelitis Tibia, Tibial Fractures","enrollment":497},{"nctId":"NCT04041791","phase":"PHASE3","title":"A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-08-19","conditions":"Pneumonia","enrollment":4392},{"nctId":"NCT04140786","phase":"PHASE1, PHASE2","title":"Optimizing IV Gentamicin in JEB","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2019-10-31","conditions":"Junctional Epidermolysis Bullosa","enrollment":6},{"nctId":"NCT03294395","phase":"PHASE3","title":"New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea","status":"COMPLETED","sponsor":"Public Health Service of Amsterdam","startDate":"2017-09-18","conditions":"Gonorrhea","enrollment":346},{"nctId":"NCT02698735","phase":"PHASE1, PHASE2","title":"Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2016-02-25","conditions":"Recessive Dystrophic Epidermolysis Bullosa","enrollment":5},{"nctId":"NCT03476941","phase":"PHASE2","title":"Antibiotic Irrigations for Intra-Abdominal Drains","status":"RECRUITING","sponsor":"Paolo Goffredo","startDate":"2019-04-01","conditions":"Abdominal Abscess","enrollment":50},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BALANCE DISORDER"},{"count":2,"reaction":"CEREBELLAR SYNDROME"},{"count":2,"reaction":"DEAFNESS NEUROSENSORY"},{"count":2,"reaction":"DIZZINESS"},{"count":2,"reaction":"FALL"},{"count":2,"reaction":"VESTIBULAR DISORDER"},{"count":1,"reaction":"CERUMEN IMPACTION"},{"count":1,"reaction":"DIFFICULTY IN WALKING"},{"count":1,"reaction":"ERYTHEMA"},{"count":1,"reaction":"EYE PAIN"}],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["no other names","Gentamicin, Garamycin"],"phase":"phase_3","status":"active","brandName":"Gentamicin Sulfate, Injectable","genericName":"Gentamicin Sulfate, Injectable","companyName":"Public Health Service of Amsterdam","companyId":"public-health-service-of-amsterdam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gentamicin sulfate is an aminoglycoside antibiotic that binds to bacterial 30S ribosomal subunits and inhibits protein synthesis, leading to bacterial cell death. Used for Serious gram-negative bacterial infections (sepsis, urinary tract infections, respiratory tract infections), Gram-positive infections in combination therapy, Empiric therapy for suspected aerobic gram-negative infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}